Third‑quarter sales of GLP‑1 receptor agonists exceeded $20 billion, driven by strong demand for Lilly’s Mounjaro and new entrants such as Zepbound. The data, compiled by BioCentury, underscore the rapid commercial expansion of incretin‑based obesity and diabetes therapies and their impact on payer negotiations, clinical practice, and R&D prioritization across the biopharma sector. Manufacturers are scaling supply and pursuing cardiovascular and oncologic outcome studies.